You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌礼制药(01672.HK)FASN抑制剂II期临床试验之中国队列取得良好顶线数据
阿思达克 03-09 08:20
歌礼制药(01672.HK)旗下全资附属公司甘莱制药与Sagimet Biosciences联合宣布,脂肪酸合成(酉每)(Fatty Acid Synthase,简称FASN)抑制剂ASC40(国外代号为TVB-2640)在随机、安慰剂对照II期临床试验的中国队列中取得良好顶线数据(topline results)。口服、每日一次的ASC40有望成为治疗非酒精性脂肪性肝炎(NASH)的药物。

初步数据显示,ASC40显着降低肝脏脂肪含量(该试验的主要疗效终点),应答率达50%。受试者的丙氨酸氨基转移(酉每)(ALT,一种与炎症相关的肝脏(酉每))也表现出显着改善。中国队列数据与2020年11月发表於美国肝病研究协会(AASLD)肝病会议上的美国队列数据结果一致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account